Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

NCT07132801 | Not Yet Recruiting

• 1 other identifier: QLS-014
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Conditions

NAD; NAD+ Levels in the Blood

Keywords

NAD Supplementation; NAD

Outcome Measures

Primary Outcomes (1)

• Between-group change in intracellular NAD⁺ levels

  To assess between-group differences in the change in intracellular NAD⁺ levels from baseline to Week 4 following supplementation with Qualia NAD version 1, Qualia NAD version 2, or placebo.

  28 days

Secondary Outcomes (4)

• Aging-Related Symptoms (AMFS scores)

  4 weeks

• RAND SF-36 Scale Scores

  4 weeks

• Side effect profile as measured by a custom Safety and Tolerability survey

  Week 1, 2, 3, and 4

• Within-group differences in the change in intracellular NAD⁺ levels

  4 weeks

Study Arms (3)

Qualia NAD⁺ version 1

ACTIVE COMPARATOR

Dietary Supplement: Qualia NAD⁺ version 1

Qualia NAD⁺ version 2

ACTIVE COMPARATOR

Dietary Supplement: Qualia NAD⁺ version 2

Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

Qualia NAD⁺ version 1 DIETARY_SUPPLEMENT

Qualia NAD+ version 1 manufactured by Qualia Life Sciences

Qualia NAD⁺ version 1

Qualia NAD⁺ version 2 DIETARY_SUPPLEMENT

Qualia NAD+ version 2 manufactured by Qualia Life Sciences

Qualia NAD⁺ version 2

Placebo DIETARY_SUPPLEMENT

Rice Flour

Placebo

Eligibility Criteria

• Age: 35 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.
• Healthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks/shots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study

You may not qualify if:

• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent

Sponsors & Collaborators

• Qualia Life Sciences: lead

Study Sites (1)

Qualia Life Sciences

Carlsbad, California, 92011, United States

Location

Central Study Contacts

William Scuba

CONTACT

855-281-2328; support@qualialife.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 13, 2025
• First Posted: August 20, 2025
• Study Start: October 13, 2025
• Primary Completion: November 30, 2025
• Study Completion: December 15, 2025
• Last Updated: August 20, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)